Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery

Next Previous
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iron-sucrose/tin-protoporphyrin (Primary)
  • Indications Acute kidney injury
  • Focus Registrational; Therapeutic Use
  • Acronyms PROTECT
  • Sponsors Renibus Therapeutics

Most Recent Events

  • 24 Apr 2025 According to a Renibus Therapeutics media release, company announced the completion of enrollment, the trial enrolled 423 patients across 40 trial sites in the United States (US) and Canada. Topline results from the study are anticipated in third quarter of 2025.
  • 24 Apr 2025 Status changed from recruiting to active, no longer recruiting.
  • 07 Mar 2025 Planned number of patients changed from 400 to 450.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top